

**GIRARD SHARP LLP**

Dena C. Sharp (State Bar No. 245869)  
Adam E. Polk (State Bar No. 273000)  
Nina R. Gliozzo (State Bar No. 333569)  
Patrick T. Johnson (State Bar No. 329580)  
601 California Street, Suite 1400  
San Francisco, CA 94108  
Telephone: (415) 981-4800  
Email: dsharp@girardsharp.com  
Email: apolk@girardsharp.com  
Email: ngliozzo@girardsharp.com  
Email: pjohnson@girardsharp.com

*Counsel for Plaintiffs and the Proposed Class*

[Additional Counsel on Signature Page]

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

F.G. and H.I., T.U. and V.W., individually and  
on behalf of all others similarly situated,

Plaintiffs,

v.

COOPERSURGICAL, INC.; THE COOPER  
COMPANIES, INC.; and DOES 1-10,  
inclusive,

Defendants.

Case No. 4:24-cv-01261-JST

**FIRST AMENDED CLASS ACTION  
COMPLAINT**

1. Strict Products Liability – Manufacturing Defect
2. Strict Products Liability – Design Defect
3. Strict Products Liability – Failure to Warn
4. Negligent Failure to Recall
5. Negligence and/or Gross Negligence;
6. Trespass to Chattels;
7. Unjust Enrichment

**DEMAND FOR JURY TRIAL**

**INTRODUCTION**

1  
2 1. This is a class action on behalf of individuals who sought to build their families through in  
3 vitro fertilization (“IVF”), but their developing embryos were damaged or destroyed because they were  
4 exposed to defective culture media products made by Defendants.

5 2. Defendants CooperSurgical, Inc. (“CooperSurgical”) and The Cooper Companies, Inc.  
6 (“Cooper Companies”) manufacture, market, and sell products to fertility clinics, including a culture  
7 media product designed to support the growth and development of embryos created through IVF. The  
8 culture media is a nutrient-rich liquid that surrounds a fertilized egg during the incubation period to help it  
9 develop into a viable embryo as part of the IVF process.

10 3. In December 2023, CooperSurgical recalled certain lots of its culture media products,  
11 which had been sold to hundreds of fertility clinics across the United States, based on evidence that they  
12 were defective and could actually harm and destroy embryos instead of helping them grow.

13 4. Plaintiffs F.G. and H.I. are a married couple that sought fertility treatment at a fertility  
14 clinic in New York, undergoing the invasive, expensive, and emotionally taxing process of IVF in the  
15 hopes of having biological children.

16 5. Plaintiffs T.U. and V.W. are a couple that sought fertility treatment at a fertility clinic in  
17 Northern California, undergoing the expensive and emotionally taxing process of IVF in the hopes of  
18 having children. To maximize their chances, Plaintiffs T.U. and V.W. secured donor eggs from a young,  
19 healthy donor. Their plan was to implant the healthy embryos in Plaintiff T.U.’s uterus so that she could  
20 experience carrying their child to term.

21 6. Unfortunately, Plaintiffs’ fertility clinics used Defendants’ defective culture media  
22 products. Using H.I.’s sperm, their clinic fertilized F.G.’s eggs and placed them in CooperSurgical’s  
23 culture media, on the expectation that it would help the fertilized eggs develop into viable embryos. And,  
24 using V.W.’s sperm, their clinic successfully fertilized six donor eggs and placed them in  
25 CooperSurgical’s culture media, on the expectation that it would help the fertilized eggs develop into  
26 viable embryos.

27 7. Four of F.G.’s eggs were fertilized, but tragically, all of the resulting embryos stopped  
28 growing before reaching viability and were destroyed as a result of Defendants’ defective culture media.

8. Similarly, six of T.U. and V.W.'s eggs were fertilized, all but one of the resulting embryos stopped growing before reaching viability and were destroyed as a result of Defendants' defective culture media. The remaining embryo was genetically tested, but the results indicated that it was genetically abnormal and thus could not be used to start a pregnancy.

9. Because of Defendants' manufacturing, marketing, promoting, distributing, and/or selling their defective culture media, Plaintiffs lost invaluable, irreplaceable property—embryos that could have grown into their children—and were emotionally, physically, and psychologically damaged. Plaintiffs bring this action to hold Defendants accountable for their conduct.

10. Plaintiffs, on behalf of themselves and all other similarly situated individuals, seek damages, equitable relief, and other remedies from Defendants.

### **JURISDICTION AND VENUE**

11. This Court has subject matter jurisdiction under the Class Action Fairness Act of 2005, 28 U.S.C. § 1332(d), because (a) Plaintiffs are a citizen of a state different from CooperSurgical and Cooper Companies, (b) the amount in controversy exceeds \$5,000,000, excluding interest and costs, (c) the proposed class consists of more than 100 individuals, and (d) none of the exceptions under the subsection applies to this action.

12. This Court has personal jurisdiction over Defendants. They conduct substantial business in this District and intentionally availed themselves of the laws and markets of this District, and Cooper Companies resides in this district. A significant portion of the acts and omissions complained of occurred in the District.

13. Venue is proper in this District under 28 U.S.C. § 1391 because Cooper Companies resides in this district and a substantial part of the events or omissions giving rise to this action occurred in this district.

### **INTRADISTRICT ASSIGNMENT**

14. Assignment to the San Francisco or Oakland Division is proper under Local Rules 3-2(c) and (d) because a substantial part of the events or omissions giving rise to Plaintiffs' claims occurred in Contra Costa county.

**PARTIES**

15. Plaintiff F.G. is a citizen and resident of Richmond, Virginia.

16. Plaintiff H.I. is a citizen and resident of Richmond, Virginia.

17. Plaintiff T.U. is a citizen and resident of San Jose, California.

18. Plaintiff V.W. is a citizen and resident of San Jose, California.

19. Given the sensitive nature of their claims, Plaintiffs are using randomized initials to protect their privacy. The Court entered an Order on the parties' stipulation agreeing to certain procedures to proceed using pseudonyms. *See* Dkt. 39.

20. Defendant The Cooper Companies, Inc. is a Delaware corporation with its principal place of business in San Ramon, California, in Contra Costa County.

21. Defendant CooperSurgical, a wholly owned subsidiary of Cooper Companies, is a Delaware corporation with its principal place of business in Trumbull, Connecticut.

22. CooperSurgical and Cooper Companies were principals, agents, alter egos, joint venturers, partners, or affiliates of each other, and in doing the acts alleged herein, were acting within the course and scope of that principal, agent, alter ego, joint venture, partnership, or affiliate relationship.

23. DOEs 1-10 are persons or entities of unknown places of residence or states of incorporation that perpetrated the wrongdoing alleged herein. Plaintiffs will attempt to identify DOEs 1-10 through discovery served on Defendants and third parties with whom Defendants interacted.

**FACTUAL ALLEGATIONS**

**A. In Vitro Fertilization Procedure**

24. IVF has become an established means of allowing individuals and couples the opportunity to become pregnant using their biological material. IVF provides the flexibility to begin a family when it makes sense for individuals and couples personally and professionally. IVF is also a way for those suffering from infertility to start their families, using their own biological material.

25. An IVF cycle typically includes the following steps or procedures: (1) the patient takes medications, including regular injections of hormones, to grow multiple eggs; (2) the clinic retrieves the patient's eggs from the ovary or ovaries; (3) the eggs are inseminated with sperm; (4) the clinic cultures any resulting fertilized eggs, fostering their development into embryos, including with the use of culture

1 media; (5) one or more embryo(s) are placed (“transferred”) into the patient’s uterus; and (6) the patient  
2 takes additional hormones to support of the uterine lining to permit and sustain pregnancy.

3 26. In certain cases, additional procedures may be employed, including (1) intracytoplasmic  
4 sperm injection (“ICSI”) to increase the chance for fertilization; (2) assisted hatching of embryos to  
5 potentially increase the chance of embryo attachment (“implantation”); and (3) cryopreservation  
6 (freezing) of eggs or embryos.

7 27. The success of IVF largely depends on growing multiple eggs at once and then retrieving  
8 the eggs (egg retrieval process). To achieve this goal, patients undergo a strict regimen of injections with  
9 hormones and other medicines. These injections can cause a plethora of known side effects, including but  
10 not limited to bruising, redness, swelling, or discomfort at the injection site, bloating, weight gain, water  
11 retention, bone loss, fatigue, headaches, muscle aches, abdominal pain, breast tenderness, vaginal yeast  
12 infections, vaginal dryness, bone loss, hot flashes, mood swings, depression, nausea, vomiting, diarrhea,  
13 clots in blood vessels and strokes. Women injected with these pharmaceuticals also run the risk of a  
14 potentially fatal allergic reaction to the drugs. And up to 2% of women will develop Ovarian  
15 Hyperstimulation Syndrome (“OHSS”), a life-threatening condition that can cause increased ovarian size,  
16 nausea and vomiting, accumulation of fluid in the abdomen, breathing difficulties, increased  
17 concentration of red blood cells, kidney and liver problems, blood clots, kidney failure, and death.

18 28. IVF requires multiple doctor visits involving routine blood tests and invasive transvaginal  
19 ultrasound examinations, which are often scheduled with very little advanced warning. IVF also places  
20 restrictions on diet, work, and travel.

21 29. The egg retrieval process itself involves surgery conducted under anesthesia, where the  
22 eggs are extracted with a large needle inserted through the vaginal wall. Risks of the egg retrieval  
23 procedure include infection, bleeding, trauma to intra-abdominal organs, allergic reactions, low blood  
24 pressure, nausea, vomiting, and in rare cases, death. After the retrieval procedure, a patient often  
25 experiences residual pain for about a week and may need bedrest for several days.

26 30. Another potential risk is that the procedure will fail to obtain any eggs, or the eggs may be  
27 abnormal or of poor quality and otherwise fail to produce a viable pregnancy.

1           31.     Based on their age and medical status, women may undergo multiple rounds of retrievals  
2 to obtain enough eggs or embryos to achieve their reproductive goals. This process can take months or  
3 even years. On average, women and couples spend \$40,000-\$60,000 out of pocket for these services.

4           32.     If and when viable eggs are retrieved, IVF and embryo culture occurs. Sperm and eggs are  
5 placed together in specialized conditions (culture media, controlled temperature, humidity, and light) to  
6 achieve fertilization. Sperm and eggs are submerged in culture media, which is a nutrient-rich liquid  
7 designed to promote the growth and development of a fertilized egg into a viable embryo by replicating  
8 the natural environment and fluids in a woman's reproductive system. When they develop successfully,  
9 embryos grow and reach certain milestones for viability over the course of several days following  
10 insemination.

11           33.     After the egg retrieval process, IVF patients can either receive a fresh embryo transfer or a  
12 frozen embryo transfer. A fresh transfer occurs after a few days of embryo development. Embryos are  
13 selected for transfer and are placed in the uterine cavity with a tube. By contrast, a frozen transfer  
14 involves cryogenically freezing the embryo, then after a period of time, unthawing the embryo and  
15 placing it in the patient's uterus. Frozen transfers allow a patient to elect to genetically screen the embryos  
16 to determine if any suffer from genetic abnormalities making them unsuitable for transfer. If multiple  
17 viable embryos are created in an IVF cycle, patients can opt to do a fresh transfer of one or more embryos  
18 and freeze others for later transfer attempts. Excess embryos of sufficient quality that are not transferred  
19 can be frozen. So long as they are properly stored, frozen embryos can remain viable and be transferred  
20 years after they are retrieved.

21           **B.     The Loss of Eggs and Embryos Has Severe Consequences**

22           34.     People who engage in fertility services make large monetary and emotional investments.  
23 They endure painful and invasive procedures, financial stress, and the strain the process puts on their  
24 mental health and relationships with others, all in the hopes that one day they will be able to have a child.

25           35.     In addition to the physical burdens of IVF, the process is also emotionally grueling. The  
26 success or failure of IVF, including egg retrieval and embryo storage, has substantial emotional and  
27 psychological ramifications for those seeking to become parents.  
28

36. For many, the IVF process represents their last hope for having children. Many women experience and express strong feelings of anxiety, failure, hopelessness, and disappointment during this process. The IVF process can affect a patient and her spouse or partner medically, financially, socially, emotionally, and psychologically. Feelings of anxiety, depression, isolation, and helplessness are not uncommon in patients undergoing IVF. Losing eggs and embryos provokes fear, devastation, and despair. Many people experience grief and anguish when fertility treatment does not result in pregnancy or when they lose fertility choices.

37. As discussed above, women take drug and hormone cocktails and injections over several weeks to stabilize the uterine lining, stimulate ovaries into producing follicles, and stop these ovary follicles from releasing eggs. A woman may be subjected to multiple injections each day, resulting in bruising, swelling, and discomfort. The drug and hormone therapy may also trigger other side effects, such as tiredness, nausea, headaches, and blood clots, as well as negative emotions. The process can limit travel and other activities, entails numerous doctor visits, and often requires time off from work. The retrieval procedure itself requires anesthesia, as well as insertion of a thick needle through the vaginal wall to drain the ovary follicles of their fluid. After the procedure, a woman often experiences residual pain for about a week and may need bed rest for several days. Some women suffer significant side effects, such as ovarian hyperstimulation syndrome, requiring hospitalization.

38. These invasive services are expensive. According to recent estimates, “a single IVF cycle—defined as ovarian stimulation, egg retrieval and embryo transfer—can range from \$15,000 to \$30,000, depending on the center and the patient’s individual medication needs.”<sup>1</sup> Clients typically pay thousands of dollars for fertility drugs leading up to egg retrieval and may also spend hundreds of dollars on acupuncture and other services recommended to them to improve outcomes. Depending on age and health status, some women will undergo (and pay for) more than one IVF cycle, or if they freeze multiple embryos, will pay thousands of dollars for each transfer attempted with an existing embryo.

39. Defendants are aware of the lengths to which people go to obtain eggs and create embryos, how much they mean to patients, the patients’ emotional (and financial) investment in the survival of the

---

<sup>1</sup> <https://www.forbes.com/health/womens-health/how-much-does-ivf-cost/>.




eggs and embryos, and the patients' expectations that great care will be taken to preserve and protect the eggs and embryos to avoid irreparable, devastating harm.

40. Eggs and embryos are precious. They offer the opportunity to fulfill one of the most fundamental human urges: to become a parent and create one's own family when the time is right. Eggs and embryos are also irreplaceable. The most determinative factor in IVF success is the woman's age at the time her eggs were extracted. At some point, usually around her mid-40s, a woman can no longer produce viable eggs. When preserved eggs or embryos are damaged or compromised, it may be impossible for clients to build their family as they had planned.

### C. Defendants Manufacture and Sell Culture Media for Growing Embryos

41. Cooper Companies consists of two business units: 1) CooperVision, which manufactures contact lenses; and 2) CooperSurgical, which manufactures fertility products and medical devices for the women's healthcare market. Cooper Companies represents that "Our two business units," CooperVision and CooperSurgical, comprise "who we are," as shown in the image from its website below.<sup>2</sup>



42. Operating through CooperSurgical, Defendant Cooper Companies is a prominent leader in the global IVF market.

43. The Cooper Companies has close involvement of in the operations of CooperSurgical. Cooper Companies employs and controls CooperSurgical's top executive, President Holly Sheffield,

<sup>2</sup> <https://www.coopercos.com/our-company/>.



1 whose employment agreement is exclusively with Cooper Companies.<sup>3</sup> CooperSurgical’s four principals  
 2 are all employed in California, and its mailing address is listed as the same California address as for The  
 3 Cooper Companies: 6101 Bollinger Canyon Rd., Suite 500, San Ramon, California.<sup>4</sup>

4 44. Cooper Companies claims that “[w]e elevate standards of care with best-in-class devices  
 5 for . . . women’s health, and fertility.”<sup>5</sup>

6 45. CooperSurgical describes itself as “a leading fertility and women’s health company  
 7 dedicated to putting time on the side of women, babies, and families at the healthcare moments that  
 8 matter most in life.”<sup>6</sup>

9 46. Together, Defendants have positioned themselves as leaders in the reproductive health and  
 10 infertility treatment fields.

11 47. Specifically describing its role in the fertility space, CooperSurgical’s website promises  
 12 that “[w]hen you partner with us you become part of a truly global network of scientific leaders,  
 13 embryologists and clinical training experts, ready to support you with highly specialized solutions, both  
 14 for individual clinics and across large organizations. By providing you with optimal products, service and  
 15 training our aim is to offer you the best possible support to drive the efficiency of your clinic – and  
 16 achieve the best possible results.”<sup>7</sup>

---

17  
 18  
 19 <sup>3</sup> See Cooper Companies FY23 Form 10-K (December 8, 2023); *see also* Employment agreement  
 20 between The Cooper Companies and Holly Sheffield (incorporated and attached to Cooper Companies  
 21 2023 10-K). Under her employment agreement with The Cooper Companies, Ms. Sheffield “shall  
 22 render exclusive, full-time services to [The Cooper Companies, Inc.] and its subsidiaries, and exercise  
 23 such authority and perform such duties as assigned to [Ms. Sheffield] by [The Cooper Companies’]  
 Chief Executive Officer (the ‘CEO’).” *Id.* Ms. Sheffield “shall perform services under this Agreement  
 primarily at [The Cooper Companies’] office in Pleasanton, California[.]” *Id.* Duties may be modified  
 “at the sole discretion of the CEO” or Cooper Companies’ Board of Directors. *Id.*

24 <sup>4</sup> See CooperSurgical’s 2024 Annual Report to Connecticut Secretary of State. The Report lists three of  
 25 four principals in California: Cynthia Wallace, Secretary, San Ramon, California; Agostino Ricupati,  
 26 Director, San Ramon, California; and Brian Andrews, Treasurer and Vice President, San Ramon,  
 27 California. *Id.* The fourth, Holly Sheffield, lists the Trumbull, Connecticut business address of  
 28 CooperSurgical, but her employment agreement states that she works primarily in Pleasanton,  
 California. *See supra* n.2.

<sup>5</sup> <https://www.coopercos.com/improving-lives/#elevating>.

<sup>6</sup> <https://www.coopersurgical.com/about-us>.

<sup>7</sup> <https://fertility.coopersurgical.com/about-us/>.

1           48.     CooperSurgical advertises its embryo culture media product, called Global Media, as a  
 2 “Single-step medium for uninterrupted embryo culture,” noting that it is “[d]esigned for D1-5 embryo  
 3 culture and transfer,” “[c]ontains energy substrates and essential amino acids to support embryo growth  
 4 and development,” and “[t]he performance of global has been demonstrated through 15 years of use and  
 5 500 independent publications using global medium.”<sup>8</sup>


6           49.     Culture media for embryo development is designed to meet the nutritional needs of  
 7 developing embryos by providing necessary sources of energy, nutrients, and pH levels based on the  
 8 specific developmental stage of the embryo. Embryo culture media is typically comprised of multiple  
 9 ingredients including carbohydrates, amino acids, vitamins, magnesium, and growth factors. The nutrients  
 10 in the media are crucial to an embryo’s successful growth.

11           50.     Magnesium is required for embryonic development and is a key element to repair  
 12 mutations during cell division. Insufficient magnesium levels in embryo culture media can cause embryo  
 13 growth to arrest and inhibit DNA repair.

14           51.     Defendants are aware of the lengths families engaged in IVF go to extract eggs and create  
 15 embryos, their emotional and financial investment in the survival of their embryos, and their expectations  
 16 that their embryos will be handled with care to avoid irreparable, devastating harm. CooperSurgical’s  
 17 website includes patient testimonials from families struggling with infertility, as shown in the screenshot  
 18 from the website below, including articles titled “Christina’s Story: Mosaic Embryo Transfer,” “What I  
 19 wish everyone knew about fertility,” and “I endured a year and a half of constant infertility efforts.”<sup>9</sup>  
 20  
 21  
 22  
 23  
 24  
 25  
 26

27 <sup>8</sup> <https://www.coopersurgical.com/product/global>; *see also*  
 28 [https://fertility.coopersurgical.com/art\\_media/global/](https://fertility.coopersurgical.com/art_media/global/).

<sup>9</sup> [https://www.coopersurgical.com/patients/patient-article-  
 list?refinementList%5Blife\\_stage\\_name%5D%5B0%5D=I%20want%20kids](https://www.coopersurgical.com/patients/patient-article-list?refinementList%5Blife_stage_name%5D%5B0%5D=I%20want%20kids).



52. Defendants recognize that they engage in a peculiarly sensitive and emotional business by manufacturing and supplying IVF products used by families who face barriers to conceiving a healthy child.

53. CooperSurgical's fertility division is highly profitable. Its CEO acknowledged that CooperSurgical experienced twelve consecutive quarters of "double-digit" growth in its fertility division, generating \$1.2 billion in revenue last year.<sup>10</sup>

#### **D. Recall of Defendants' Embryo Culture Media**

54. In a letter dated December 5, 2023, CooperSurgical issued an Urgent Recall Notice for certain lots of its Global Media culture product.<sup>11</sup> Global Media Lots number 231020-018741, 231020-018742, and 231020-018743 were recalled, with part numbers LGGG-100, LGGG-50, and LGGG-20.

55. The Recall Notice states "CooperSurgical has become aware of a sudden increase in complaints regarding the aforementioned lots of this product," acknowledged that the "risk to health is

<sup>10</sup> <https://www.lawweekly.com/coopersurgical-recalls-faulty-i-v-f-liquid-destroying-embryos/>.

<sup>11</sup> Exhibit A, Cooper Surgical Recall Notice (December 5, 2023).

1 impaired embryo development prior to the blastocyst stage,” and directed clinics who purchased the  
2 product to quarantine and return it.<sup>12</sup>

3 56. According to regulatory authorities, CooperSurgical issued the recalls because the recalled  
4 batches of the Global Media were deficient in magnesium.<sup>13</sup>

5 57. Defendants knew or should have known that magnesium is a critical component and  
6 essential element of embryo culture media, and that a lack of magnesium in the Global Media may result  
7 in the destruction or arrested development of human embryos.

8 58. Defendants nevertheless failed to adequately monitor their manufacturing systems and  
9 processes, and allowed for the production of embryo culture media without ensuring that sufficient  
10 amounts of magnesium was included.

11 59. Defendants did not properly test or inspect the impacted lots of Global Media until after  
12 receiving numerous complaints from fertility clinics that embryos cultured in Defendant’s Global Media  
13 were dying at elevated rates.

14 60. The FDA posted a notice on its website regarding the recall in February 2024, estimating  
15 that 994 bottles of culture media were affected, 481 of which were purchased by clinics across the United  
16 States.<sup>14</sup>

17 61. A New York Times article on the recall reported that, according to Mitchel C. Schiewe, an  
18 embryologist and a laboratory director at California Fertility Partners, “each bottle holds enough liquid  
19 for multiple patients, though it’s unclear how many bottles were opened before the December recall. If  
20 clinics used even half of the affected bottles, as many as 20,000 patients could have been affected.”<sup>15</sup>

---

23 <sup>12</sup> *Id.*

24 <sup>13</sup> <https://www.lawweekly.com/coopersurgical-recalls-faulty-i-v-f-liquid-destroying-embryos/>  
25 (“Regulatory authorities have revealed that CooperSurgical issued recalls for several batches of its  
I.V.F. product due to a crucial nutrient, Magnesium, being deficient”).

26 <sup>14</sup> <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205122> (noting distribution of  
27 the recall product in the United States “Nationwide including in the states of AL, AZ, CA, CO, FL, GA,  
28 IL, IN, IA, KS, KY, LA, MD, MA, MI, MO, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, TN, TX,  
UT, VT, VA, WA, WV”).

<sup>15</sup> <https://www.nytimes.com/2024/02/15/health/cooper-surgical-ivf-embryos-lawsuits.html>.

**E. Plaintiffs were harmed by Defendants' Defective Culture Media**

**F.G. and H.I.**

62. F.G. and H.I. are a married couple that sought help growing their family through IVF treatment.

63. F.G. and H.I. engaged in IVF treatment at CNY Fertility in Albany, New York. The IVF process produced four fertilized eggs that were to be developed into viable embryos.

64. On or around November 2023, Plaintiffs' fertility clinic fertilized four of F.G.'s eggs with H.I.'s sperm and placed them in Defendants' culture media.

65. Each of the four eggs was successfully fertilized, but all of F.G. and H.I.'s developing embryos were destroyed due to Defendants' defective culture media.

66. F.G. and H.I. were notified in February 2024 that all of their embryos were exposed to the defective culture media, which was subject to a recall. Plaintiffs' fertility clinic advised them that "While [CooperSurgical] has not completed the investigation, they do believe that the issues observed in the field are likely due to a reduced level of magnesium in the media. Lower levels of magnesium could impact embryo development."

67. The embryos that F.G. and H.I. lost are irreplaceable. F.G. is older now that she was at the time the eggs used to create the lost embryos were retrieved. As a result, even if Plaintiffs are able to create additional embryos—a physically, emotionally, and financially costly procedure that is by no means guaranteed to succeed—those embryos made with older eggs would not have as high of a chance of successfully developing into a healthy child or children.

**T.U. and V.W.**

68. T.U. and V.W. are a couple who sought help growing their family through IVF treatment.

69. T.U. and V.W. engaged in IVF treatment at Zouves Fertility Center in Foster City, California. The IVF process produced six fertilized eggs that were to be developed into viable embryos.

70. On or around December 8, 2023, using V.W.'s sperm and donor eggs, Plaintiffs' fertility clinic fertilized six of the donor eggs and placed them in Defendants' culture media.

71. Each of the six eggs was successfully fertilized, but all but one of T.U. and V.W.'s developing embryos were destroyed due to Defendants' defective culture media. The remaining embryo

1 developed to blastocyst, but was later determined through genetic testing to be chromosomally abnormal  
2 and thus unusable.

3 72. T.U. and V.W. were notified on or around February 15, 2024, via email, that all of their  
4 embryos were exposed to the defective culture media, which was subject to a recall. Plaintiffs' fertility  
5 clinic advised them as follows:

6 We have been informed by CooperSurgical, the supplier of the culture medium  
7 LifeGlobal® global® media that was used in your cycle performed at ZFC in December  
8 2023, that your cycle may have been negatively affected by a quality control issue with  
9 this batch of media. This quality control issue could have resulted in fewer embryos than  
10 you would otherwise have made embryo development [sic].

11 73. The embryos Plaintiffs lost are irreplaceable. Plaintiffs T.U. and V.W. are both older now.  
12 As a result, even if Plaintiffs are able to afford to create additional embryos—an emotionally taxing and  
13 financially costly procedure that is by no means guaranteed to succeed—those embryos made with older  
14 sperm may not have as high of a chance of successfully developing into a healthy child or children, and  
15 Plaintiff T.U. faces heightened risks of possible health complications from carrying a child to term.

### 16 **CLASS ACTION ALLEGATIONS**

17 74. Plaintiffs bring this action, on behalf of themselves and all others similarly situated, as a  
18 class action pursuant to Federal Rule of Civil Procedure 23(b)(1), 23(b)(2), 23(b)(3), and where  
19 applicable, 23(c)(4), on behalf of the following Class:

20 All individuals in the United States whose eggs and/or embryos were exposed to  
21 Recalled Lots of Defendants' Global Media product (Global Media Lots number  
22 231020-018741, 231020-018742, and 231020-018743).

23 Plaintiffs reserve the right to modify, expand, or narrow the proposed Class definition, including based on  
24 discovery and further investigation.

25 75. Excluded from the class are Defendants, their affiliates and subsidiaries, and their officers,  
26 directors, partners, employees, and agents; class counsel, their immediate family members, and  
27 employees of their firms; counsel for Defendants, their immediate family members, and employees of  
28 their firms; and judicial officers assigned to this case and their staffs and immediate family members.

76. Numerosity. The members of the class are so numerous that their individual joinder is  
impracticable. There are at least hundreds of class members, whose names and addresses can be discerned

1 from Defendants' records and the records of the fertility clinics who used the Recalled Lots of  
 2 Defendants' Global Media product.

3 77. Existence and Predominance of Common Questions of Fact and Law. This action involves  
 4 common questions of law and fact that predominate over any questions affecting individual class  
 5 members, including, without limitation:

- 6 a. Whether the Recalled Lots of Defendants' embryo culture media were defectively  
 7 manufactured;
- 8 b. Whether the Recalled Lots of Defendants' embryo culture media were defectively  
 9 designed;
- 10 c. Whether Defendants are strictly liable for failing to recall the Recalled Lots of embryo  
 11 culture media sooner;
- 12 d. Whether Defendants negligently failed to recall the Recalled Lots of embryo culture media  
 13 sooner;
- 14 e. Whether any defect in the Recalled Lots of Defendants' embryo culture media resulted  
 15 from Defendants' negligence or other wrongful conduct;
- 16 f. Whether Defendants failed to take adequate and reasonable measures to ensure that their  
 17 embryo culture media would be safely made;
- 18 g. Whether Defendants owed a duty to Plaintiffs and class members to protect the developing  
 19 embryos entrusted to Defendants' care through the use of its embryo culture media  
 20 product;
- 21 h. Whether Defendants breached their duties to protect the developing embryos that Plaintiff  
 22 and class members entrusted to their care through the use of its embryo culture media  
 23 product;
- 24 i. Whether Defendants trespassed the chattels of Plaintiffs and class members by damaging  
 25 their personal property—developing embryos—through exposure to Defendants' defective  
 26 culture media;
- 27 j. Whether Defendants were unjustly enriched through their conduct; and  
 28



k. Whether Plaintiff and class members suffered harm as a result of Defendants' violations and, if so, the appropriate measure of damages, restitution, or rescission.

78. Typicality. Plaintiffs' claims are typical of the other class members' claims because Plaintiffs and class members were subjected to the same wrongful conduct and damaged in the same way by having their developing embryos damaged or destroyed through exposure to Defendants' defective culture media.

79. Adequacy of Representation. Plaintiffs are adequate class representatives. Their interests do not conflict with the interests of the other class members they seek to represent. They have retained counsel competent and experienced in complex class action litigation, and they intend to prosecute this action vigorously. Plaintiffs and their counsel will fairly and adequately pursue and protect the interests of the class.

80. Superiority. A class action is superior to all other available means for the fair and efficient adjudication of this controversy. The damages or other financial detriment suffered by Plaintiffs and the other class members are relatively small compared to the burden and expense that would be required to individually litigate these claims. As a result, it would be impracticable for many class members to seek redress individually. Individualized litigation would also create a potential for inconsistent or contradictory judgments and increase the delay and expense to all parties and the court system. By contrast, the class action device presents far fewer management difficulties and provides the benefits of single adjudication, economy of scale, and comprehensive supervision by a single court.

81. Class certification is also appropriate under Rules 23(b)(1), (b)(2), and/or (c)(4) because:

- The prosecution of separate actions by individual members of the Class would create a risk of inconsistent or varying adjudications establishing incompatible standards of conduct for Defendants.
- The prosecution of separate actions by individual Class members would create a risk of adjudications that would, as a practical matter, be dispositive of the interests of other Class members not parties to the adjudications, or would substantially impair or impede their ability to protect their interests.

- Defendants have acted or refused to act on grounds generally applicable to the Class, making injunctive and corresponding declarative relief appropriate with respect to the Class as a whole; and
- The claims of Class members are comprised of common issues whose resolution in a class trial would materially advance this litigation.

### **FIRST CAUSE OF ACTION**

#### **Strict Products Liability – Manufacturing Defect**

82. Plaintiffs incorporate the above and below allegations by reference.

83. Defendants are strictly liable to Plaintiffs and class members for harm caused by manufacturing defects in their culture media under California products liability law.

84. Defendants manufactured, tested, supplied, distributed, and/or sold the culture media used on Plaintiffs' and class members' embryos.

85. Defendants' culture media contained at least one manufacturing defect when it left Defendants' possession. The culture media was defective in that it differed from Defendants' intended result, did not conform to Defendants' design or specifications, and/or differed from other typical units of the same product. In particular, among other possible defects, the media lacked a sufficient level of magnesium, such that it destroyed or hindered the development of human embryos.

86. Defendants' culture media was used as intended when it came into contact with Plaintiffs' and class members' embryos.

87. The culture media's defect was a substantial factor in causing Plaintiffs' and class members' damages, including economic loss, serious emotional distress, and other harm in an amount to be determined at trial.

### **SECOND CAUSE OF ACTION**

#### **Strict Products Liability – Design Defect**

88. Plaintiffs incorporate the above and below allegations by reference.

89. In addition or as an alternative to the first cause of action, Defendants are strictly liable to Plaintiffs and class members for harm caused by design defects in the culture media under California products liability law.

1           90. Defendants manufactured, tested, supplied, distributed, and/or sold the culture media,  
2 which was defectively designed under the consumer expectations test and/or the risk-benefit test.

3           **Consumer Expectations Test**

4           91. Defendants' culture media did not perform as safely as ordinary users of culuture media  
5 expect when used or misused in an intended or reasonably foreseeable way.

6           92. Defendants' culture media caused Plaintiffs' and class members' embryos to stop  
7 developing and prevented them from reaching viability. Ordinary users do not expect culture media to  
8 prevent embryo development.

9           93. Defendants' culture media's failure to perform safely was a substantial factor in causing  
10 Plaintiffs' and class members' damages, including economic loss, serious emotional distress, and other  
11 harm in an amount to be determined at trial.

12           94. Defendants' culture media was used as intended when it came into contact with Plaintiffs'  
13 and class members' embryos.

14           **Risk-Benefit Test**

15           95. Defendants' culture media's design was a substantial factor in causing Plaintiffs' and class  
16 members' damages, including economic loss, serious emotional distress, and other harm in an amount to  
17 be determined at trial.

18           96. In particular, the culture media, which should have promoted the development of human  
19 embryos fertilized *in vitro* was defectively designed. Among other things, the culture formulation lacked  
20 a sufficient level of magnesium, causing Plaintiffs' and class members' embryos to stop developing and  
21 preventing them from reaching viability.

22           97. Any benefits to its design that Defendants may allege in answer to this complaint do not  
23 outweigh the risks of the design, taking into account the gravity of the potential harm, the likelihood the  
24 harm would occur, the feasibility of an alternative design, the cost of an alternative design, and any  
25 disadvantage associated with an alternative design.

26           98. Defendants' culture media was used as intended when it came into contact with Plaintiffs'  
27 and class members' embryos.

**THIRD CAUSE OF ACTION**

**Strict Products Liability – Failure to Warn**

99. Plaintiffs incorporate the above and below allegations by reference.

100. Defendants designed, manufactured, tested, supplied distributed, and/or sold the defective culture media, including the culture media used on Plaintiffs’ and class members’ embryos.

101. Defendants’ culture media had potential risks—including but not limited to defective formulation due to a lack of magnesium—that were known or knowable in light of the scientific and medical knowledge that was generally accepted in the scientific community at the time of the manufacture, distribution, or sale of the culture media.

102. Defendants’ culture media was defective and unreasonably dangerous when it left Defendants’ possession because it did not contain adequate warnings, including warnings concerning the risk of defect that its formulation lacked sufficient magnesium and would stop embryos development.

103. The potential risks of destroying and preventing the development of human embryos upon contact presented a substantial danger when Defendants’ culture media was used or misused in an intended or reasonably foreseeable way.

104. The ordinary consumer would not have recognized the potential for risks. Defendants knew or reasonably should have known that users may not have adequate quality control measures in place to detect the dangers of the culture media before applying it to reproductive cells, and failed to adequately warn or instruct concerning the potential risks of applying the culture media to reproductive cells when a reasonable manufacturer, distributor, or seller under similar circumstances would have warned of the danger or instructed in the safe use of the culture media.

105. Defendants had constructive notice or knowledge and knew, or in the exercise of reasonable care should have known, that the culture media was dangerous, had risks, was defective in manufacture or design, including that it would destroy and prevent the development of human embryos upon contact.

106. Defendants failed to adequately warn or instruct of the potential risks of applying its defective culture media to human reproductive material.

107. It was foreseeable to Defendants that failure to adequately warn about the risks of its culture media would cause irreparable harm to those whose embryos were exposed to it during IVF, including the types of emotional distress suffered by Plaintiffs and class members.

108. As a result of Defendants' failures to adequately warn, Plaintiffs and class members were harmed as described herein. Defendants' failure to warn was a substantial factor in causing Plaintiffs' and class members' damages, including economic loss, serious emotional distress, and other harm in an amount to be determined at trial.

109. Defendants' culture media was used as intended when it came into contact with Plaintiffs' and class members' embryos.

#### **FOURTH CAUSE OF ACTION**

## Negligent Failure to Recall

110. Plaintiffs incorporate the above and below allegations by reference.

111. Defendants designed, manufactured, tested, supplied distributed, and/or sold the defective culture media, including the culture media used on Plaintiffs' and class members' embryos.

112. Defendants acted negligently by failing to recall their defective culture media products, prior to their use in the IVF process for Plaintiffs' and class members' embryos.

113. Defendants knew or reasonably should have known that, when used as intended, the culture media presented or was likely to present a danger to developing human embryos, including that it would destroy and prevent the development of human embryos upon contact.

114. After Defendants sold the defective culture media to Plaintiffs' and class members' fertility clinics and before the defective culture media was used on Plaintiffs' and class members' embryos, Defendants knew or reasonably should have known that the culture media was insufficiently tested, monitored, and developed, and that it presented a danger to developing human embryos, including that it would destroy and prevent the development of human embryos upon contact. Nevertheless, at no point during this time period did Defendants recall, repair, or warn of the danger posed by the defective culture media.

115. A reasonable manufacturer, distributor, or seller facing the same or similar circumstances as Defendants would have recalled the defective culture media to ensure developing human embryos were not endangered.

116. Defendants' failure to timely recall the defective culture media was a substantial factor in causing harm to Plaintiffs and class members. Had Defendants recalled the defective culture media before it was used on Plaintiffs' and class members' embryos, their fertility clinics would not have used it, and it would not have destroyed, damaged, or prevented the development of Plaintiffs' and class members' embryos upon contact.

### **FIFTH CAUSE OF ACTION**

#### **Negligence/Gross Negligence**

117. Plaintiffs incorporate the above and below allegations by reference.

118. Defendants owed Plaintiffs and class members a duty to exercise the highest degree of care when they designed, produced, manufactured, assembled, sold, supplied and/or otherwise placed the defective culture media into the stream of commerce for use in the growth and development of human embryos.

119. Defendants knew or reasonably should have known that their culture media needed to be designed, produced, manufactured, assembled, maintained, inspected, sold and supplied properly, without defects and with due care, for safe use in the growth and development of human embryos. Defendants were negligent, reckless, and careless and failed to take the care and duty owed to Plaintiffs and class members, thereby causing Plaintiffs and class members to suffer harm.

120. Defendants breached this duty and were negligent in the design, manufacture, inspection, and/or testing of their embryo culture media, and produced an unsafe, dangerous, and defective embryo culture media that guaranteed the failure of embryonic viability during the IVF process.

121. Defendants could have reasonably foreseen that if Defendants' embryo culture media was defective, consumers of the embryo culture media, like Plaintiffs, would have experienced economic loss and serious emotional distress as a result of Defendants' breach of their duty of care.

122. As a direct and proximate result of Defendants' negligent acts and/or omissions, including but not limited to, failing to properly or adequately test their embryo culture media, promoting and

1 marketing their embryo culture media as properly tested and safe for use on human embryos despite their  
2 knowledge of its defective nature, defectively designing their embryo culture media, defectively  
3 manufacturing their embryo culture media, and/or failing to adequately warn of the dangerous effects of  
4 the culture media, Plaintiffs and class members were harmed as described herein, including the  
5 destruction of their developing embryos.

6 123. These negligent acts and/or omissions were a substantial factor in causing Plaintiffs' and  
7 class members' damages, including economic loss, serious emotional distress, and other harm in an  
8 amount to be determined at trial.

9 124. Imposing a duty on Defendants to avoid causing emotional distress would promote the  
10 policy of preventing future harm, insofar as they will be motivated to take steps to ensure that its embryo  
11 culture media products are free from defects capable of destroying, damaging, or jeopardizing the  
12 embryos they are designed to help develop. Imposing a duty on Defendants to avoid causing emotional  
13 distress also furthers the community's interest in ensuring that reliable fertility services are available to  
14 those who wish to become parents.

15 125. The burden on Defendants from a duty to avoid causing emotional distress is fair and  
16 appropriate, in light of the importance of the embryos they voluntarily agreed to protect, at considerable  
17 cost to Plaintiffs and class members.

18 126. Defendants' acts and omissions constitute gross negligence because they are an extreme  
19 departure from what a reasonably careful person would do in the same situation to prevent foreseeable  
20 loss of embryos during the IVF process.

21 127. Defendants acted willfully, wantonly, and with a conscious disregard for the safety of  
22 consumers and/or users of their embryo culture media, including Plaintiffs, because Defendants were  
23 aware of the dangerous consequences of not properly or adequately testing their embryo culture media,  
24 they knew or should have known the embryo culture media lacked vital nutrients such that it posed a  
25 severe risk to irreplaceable developing human embryos, and failed to recall the culture media before it  
26 was used to culture and develop Plaintiffs' and class members' embryos.



**SIXTH CAUSE OF ACTION**

**Trespass to Chattels**

128. Plaintiffs incorporate the above and below allegations by reference.

129. Plaintiffs and class members owned or had the right to possess their reproductive material—their developing embryos—that was destroyed by Defendants’ embryo culture media.

130. Defendants intentionally interfered with Plaintiffs’ and class members’ possession of their developing embryos by manufacturing a defective product that destroyed the material instead of safely culturing the fertilized eggs to develop into healthy embryos, and by failing to recall or warn about the dangers of this product before it was used on Plaintiffs’ and class members’ reproductive material.

131. Plaintiffs and class members did not consent to or authorize the use of a faulty and defective culture media on their developing embryos.

132. Defendants caused physical damage to Plaintiffs’ and class members’ personal property when the defective culture media destroyed their developing embryos.

133. Defendants impaired the condition, quality, or value of Plaintiffs’ and class members’ personal property when the defective culture media prevented the developing embryos from becoming viable.

134. Defendants’ interference with Plaintiffs’ and class members’ reproductive material proximately caused harm to Plaintiffs and class members, as described herein, including by destroying their embryos.

135. As a foreseeable, direct and proximate result of the harm to Plaintiffs’ and class members’ reproductive material caused by Defendants’ trespass, Plaintiffs and class members have suffered and continue to suffer injuries in an amount to be determined at trial, including economic loss, serious emotional distress, and other harm in an amount to be determined at trial. A reasonable person in Plaintiffs’ and class members’ position would sustain emotional distress as a result of Defendants’ conduct described herein.

**SEVENTH CAUSE OF ACTION**

**Unjust Enrichment**

136. Plaintiffs incorporate the above allegations by reference.

137. Plaintiffs and class members conferred a tangible and material economic benefit on Defendants by purchasing the defective culture media.

138. Defendants voluntarily and readily accepted and retained the benefits.

139. Plaintiffs and class members would not have purchased the culture media had they known its defective nature.

140. This benefit was obtained unlawfully. Defendants marketed their embryo culture media as being safe and effective for use on Plaintiffs' and class members' reproductive material. Defendants knew or should have known that the payments rendered by Plaintiffs and class members were given with the expectation that the embryo culture media would have the qualities, characteristics, and suitability for use represented by Defendants.

141. Defendants received benefits in the form of revenues from purchases of their culture media to the detriment of Plaintiffs and class members, who purchased defective embryo culture media that was not what Plaintiffs and class members bargained for and was not safe and effective, as claimed by Defendants.

142. It would be unjust and inequitable for Defendant to retain the benefit without paying the value thereof.

143. Defendants have been unjustly enriched in retaining the benefits derived from the purchase of defective culture media by Plaintiffs and class members. Retention of the payments received under these circumstances is unjust and inequitable because Defendants' representations and labeling of the recalled embryo culture media lots was misleading to consumers, which caused injuries to Plaintiffs and class members because they would have not purchased the culture media had they known its true, defective nature.

144. Plaintiffs and class members are entitled to restitution and to recover from Defendants all amounts wrongfully and improperly retained in the amount necessary to Plaintiffs and class members to the position they occupied prior to purchasing and being harmed by the defective culture media.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs, individually and on behalf of the class defined above, respectfully request that the Court:

- a. Certify this action as a class action under Rule 23 of the Federal Rules of Civil Procedure, appoint Plaintiffs as class representatives, and appoint the undersigned counsel as class counsel;
- b. Award Plaintiffs and class members compensatory, restitutionary, punitive, and/or exemplary damages in an amount to be determined at trial;
- c. Award prejudgment interest as permitted by law;
- d. Award reasonable attorneys' fees and costs, as permitted for by law; and
- e. Grant such other and further relief as the Court deems equitable, just, or proper.

**DEMAND FOR JURY TRIAL**

Plaintiffs demand a trial by jury on all issues so triable.

Dated: May 23, 2024

Respectfully submitted,

/s/ Dena C. Sharp

Dena C. Sharp (State Bar No. 245869)  
Adam E. Polk (State Bar No. 273000)  
Nina R. Gliozzo (State Bar No. 333569)  
Patrick T. Johnson (State Bar No. 329580)

**GIRARD SHARP LLP**

601 California Street, Suite 1400  
San Francisco, CA 94108  
Telephone: (415) 981-4800  
Email: dsharp@girardsharp.com  
Email: apolk@girardsharp.com  
Email: ngliozzo@girardsharp.com  
Email: pjohnson@girardsharp.com

Joseph G. Sauder  
Matthew D. Schelkopf  
Juliette T. Mogenson  
**SAUDER SCHELKOPF LLC**  
1109 Lancaster Avenue

Berwyn, PA 19312  
Tel: (888) 711-9975  
Facsimile: (610) 421-1326  
Email: jgs@sstrialawyers.com  
Email: mds@sstrialawyers.com  
Email: jtm@sstrialawyers.com

Tracey B. Cowan (State Bar No. 250053)  
**CLARKSON LAW FIRM, P.C.**  
95 3rd St., 2nd Floor  
San Francisco, CA 94103  
Telephone: (213) 788-4050  
Facsimile: (213) 788-4070  
Email: tcowan@clarksonlawfirm.com

Ryan J. Clarkson (State Bar No. 257074)  
Shireen M. Clarkson (State Bar No. 237882)  
Olivia E. Davis (State Bar No. 353041)  
**CLARKSON LAW FIRM, P.C.**  
22525 Pacific Coast Highway  
Malibu, CA 90265  
Telephone: (213) 788-4050  
Facsimile: (213) 788-4070  
Email: rclarkson@clarksonlawfirm.com  
Email: sclarkson@clarksonlawfirm.com  
Email: odavis@clarksonlawfirm.com

*Counsel for Plaintiffs and the Proposed Class*